Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Support

This activity is supported by educational grants from Astellas, Pfizer, Inc. and Sanofi Genzyme.

2020 Continuity in Cancer Care®: Aligning Primary Care, Urology and Oncology Specialty Care to Improve Long-Term Management of Prostate Cancer Patients

Release Date: August 25, 2020
Expiration Date: August 25, 2021

Activity Overview

This online educational activity is designed to bring together medical professionals who provide care for men with prostate cancer to discuss its management. Current and emerging treatment strategies, coordination of care, and management of treatment-related toxicities are presented in a series of videos featuring discussions between expert thought leaders in the fields of medical oncology, urology, and cardiology.

This activity is supported by educational grants from Astellas, Pfizer, Inc. and Sanofi Genzyme.

This activity is supported by educational grants from Astellas, Pfizer, Inc. and Sanofi Genzyme.

Instructions for This Activity and Receiving Credit

  1. Complete the activity (including pre- and post-activity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.

You may immediately download your certificate.

Target Audience

This educational activity is directed toward medical oncologists, urologists and primary care physicians who treat or manage patients with prostate cancer. Nurse practitioners, physicians’ assistants, nurses, pharmacists and other healthcare professionals interested in the treatment of prostate cancer are invited to participate.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

  • Discuss strategies to integrate existing and newer therapies for metastatic castration sensitive prostate cancer (mCSPC) into clinical practice
  • Outline monitoring and screening tests recommended for survivors of prostate cancer
  • Develop strategies for management of disease- and treatment-related toxicities among patients with mCSPC
  • Identify strategies to coordinate care among medical oncologist, urologist, and primary care practitioners to optimize outcomes and mitigate risk among patients with prostate cancer

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.


Robert Dreicer, MD, MS, MACP, FASCO, Faculty Chair
Robert Dreicer, MD, MS, MACP, FASCO, Faculty Chair
Professor of Medicine and Urology
University of Virginia School of Medicine
Section Head, Medical Oncology
Associate Director for Clinical Research
Deputy Director, University of Virginia Cancer Center
Codirector, Paul Mellon Urologic Cancer Institute
Charlottesville, VA

Disclosures: Grant Research Support: Exelixis, Janssen Pharmaceuticals, Seattle Genetics; Consultant: Astellas Pharma, Eisai, Genentech, Merck & Co, Novartis, Orion Corporation, Pfizer, Seattle Genetics.

Executive Director of Interventional Cardiovascular Programs,
Brigham and Women’s Hospital Heart & Vascular Center
Professor of Medicine,
Harvard Medical School
Boston, MA

Disclosures: Grant Research Support: Amarin Corporation, Amgen, AstraZeneca, Bristol-Myers Squibb, Chiesi, Eisai, Ethicon, Forest Laboratories, Ironwood Pharmaceuticals, Ischemix, Lilly, Medtronic, Pfizer, Roche, Sanofi-Aventis, The Medicines Company.

Sam S. Chang, MD, MBA
Sam S. Chang, MD, MBA
Patricia and Rodes Hart Professor of Urologic Surgery
Vanderbilt University Medical Center
Chief Surgical Officer, Vanderbilt Ingram Cancer Center
Chief, Division of Urologic Surgery
Professor, Department of Urology
Vanderbilt University Medical Center
Nashville, Tennessee

Disclosures: Consultant: Astellas Pharma, Janssen Pharmaceuticals

William K. Oh, MD
William K. Oh, MD
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Deputy Director, Tisch Cancer Institute_
Chief, Division of Hematology and Medical Oncology
Mount Sinai Health System
New York, NY

Disclosures: Consultant: Astellas Pharma, AstraZeneca, Bayer, Foundry, Janssen Pharmaceuticals, Sanofi, Sema4, TeneoBio

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.

Login or Register to Start Activity

Please use the form below to Register or Log In to begin Activity.

*Required Fields
Calendar of Events
Filter By